Advertisement

Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis

  • Zuojun Xu
  • Huiping Li
  • Fuqiang Wen
  • Chunxue Bai
  • Ping Chen
  • Feng Fan
  • Na Hu
  • Susanne Stowasser
  • Jian KangEmail author
Original Research

Abstract

Purpose

To investigate the efficacy and safety of nintedanib versus placebo in Chinese patients with idiopathic pulmonary fibrosis (IPF).

Methods

The INPULSIS® trials consisted of two replicate, randomized, placebo-controlled, double-blind trials comparing nintedanib 150 mg bid with placebo over a 52-week treatment period. The primary endpoint was annual rate of decline in forced vital capacity (FVC); key secondary endpoints were change from baseline in Saint George’s Respiratory Questionnaire’s total score and time to first investigator-reported acute exacerbation. Data from both trials were pooled for the Chinese subgroup analyses.

Results

A total of 101 Chinese patients (nintedanib/placebo: 61/40) were treated. The demographic characteristics were generally balanced between treatment arms. Over 52 weeks, the rate of decline in FVC was lower in nintedanib-treated patients compared with placebo-treated patients in the Chinese subgroup [− 126.43 vs. − 229.82 mL/year; ∆ = 103.39 mL/year (95% confidence interval, CI: − 19.40 to 226.18)]. The proportion of patients with adverse events (AEs) over 52 weeks was similar between treatment arms. The most commonly reported AEs with nintedanib treatment were gastrointestinal symptoms (diarrhoea, nausea, and vomiting).

Conclusions

Nintedanib is clinically efficacious in Chinese patients with IPF with approximately 50% reductions in the rate of decline in FVC, demonstrating slowed disease progression. Similar to the overall INPULSIS® population, nintedanib has a favourable benefit/risk profile in Chinese patients with IPF.

ClinicalTrials.gov identifiers

NCT01335464, NCT01335477.

Funding

Boehringer Ingelheim.

Plain Language Summary

Plain language summary available for this article.

Keywords

Asians Chinese Efficacy Forced vital capacity Idiopathic pulmonary fibrosis INPULSIS® Nintedanib Randomized controlled trial Respiratory Safety 

Notes

Acknowledgements

The authors would like to thank Zhancheng Gao, Peking University People’s Hospital, Beijing; Zhikui Li, Xijing Hospital, 4th Military Medical University, Xi’an; Huanying Wan, Shanghai Ruijin Hospital, Shanghai; Haoyan Wang, Beijing Friendship Hospital, Beijing; Qiming Xiao, Xiangya Hospital, Central South University, Changsha; Wei Zhang, The First Affiliated Hospital of Nanchang University, Nanchang; Xiwei Zheng, General Hospital of Ningxia Medical University, Yinchuan; Huili Zhu, Shanghai Huadong Hospital, Shanghai for their efforts during the trials in China. The authors also thank the participants of the study.

Funding

The INPULSIS® trials were funded by Boehringer Ingelheim. The article processing charges were funded by Boehringer Ingelheim.

Medical Writing and/or Editorial Assistance

Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Hui Chin Teoh during the development of this article.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Jian Kang is the guarantor of this work and, had full access to all the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Disclosures

Zuojun Xu acted as a principal investigator of the INPULSIS® trials in China, and received investigator fees for the roles. Huiping Li acted as a principal investigator of the INPULSIS® trials in China, and received investigator fees for the roles. Fuqiang Wen acted as a principal investigator of the INPULSIS® trials in China, and received investigator fees for the roles. Chunxue Bai acted as a principal investigator of the INPULSIS® trials in China, and received investigator fees for the roles. Ping Chen acted as a principal investigator of the INPULSIS® trials in China, and received investigator fees for the roles. Jian Kang acted as a principal investigator of the INPULSIS® trials in China, and received investigator fees for the roles. Feng Fan is an employee of Boehringer Ingelheim. Na Hu is an employee of Boehringer Ingelheim. Susanne Stowasser is an employee of Boehringer Ingelheim. None of the listed authors received any payment for their participation in the writing of this manuscript.

Compliance with Ethics Guidelines

This post hoc subgroup analysis is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. The main INPULSIS® trials were conducted in accordance with the principles of the Declaration of Helsinki and the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonization and were approved by local authorities. The clinical protocol was approved by an independent ethics committee or institutional review board at each participating centre. All patients provided written informed consent before study entry.

Data Availability

The datasets generated for this study can be accessed and analysed via application to the Clinical Study Data Request (CSDR) website at https://www.clinicalstudydatarequest.com.

Supplementary material

12325_2019_887_MOESM1_ESM.docx (27 kb)
Supplementary material 1 (DOCX 27 kb)

References

  1. 1.
    Kreuter M, Bonella F, Wijsenbeek M, Maher TM, Spagnolo P. Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues, and future perspectives. Biomed Res Int. 2015;2015:329481.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012;185(10):1044–8.CrossRefGoogle Scholar
  3. 3.
    Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2018;198(5):e44–68.CrossRefGoogle Scholar
  4. 4.
    Richeldi L, Cottin V, Flaherty KR, et al. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(7):1023–30.CrossRefGoogle Scholar
  5. 5.
    Olson AL, Brown KK, Swigris JJ. Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Relat Outcome Meas. 2016;7:29–35.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–6.CrossRefGoogle Scholar
  7. 7.
    Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011;66(6):462–7.CrossRefGoogle Scholar
  8. 8.
    Lai C-C, Wang C-Y, Lu H-M, et al. Idiopathic pulmonary fibrosis in Taiwan—a population-based study. Respir Med. 2012;106(11):1566–74.CrossRefGoogle Scholar
  9. 9.
    Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014;190(7):773–9.CrossRefGoogle Scholar
  10. 10.
    Dong G-H, Zhang P, Sun B, et al. Long-term exposure to ambient air pollution and respiratory disease mortality in Shenyang, China: a 12-year population-based retrospective cohort study. Respir Int Rev Thorac Dis. 2012;84(5):360–8.Google Scholar
  11. 11.
    Mo Z, Fu Q, Zhang L, et al. Acute effects of air pollution on respiratory disease mortalities and outpatients in Southeastern China. Sci Rep. 2018;8(1):3461.CrossRefGoogle Scholar
  12. 12.
    Lee M-G, Lee YH. A meta-analysis examining the association between the MUC5B rs35705950 T/G polymorphism and susceptibility to idiopathic pulmonary fibrosis. Inflamm Res. 2015;64(6):463–70.CrossRefGoogle Scholar
  13. 13.
    Xu L, Bian W, Gu X-H, Shen C. Genetic polymorphism in matrix metalloproteinase-9 and transforming growth factor-β1 and susceptibility to combined pulmonary fibrosis and emphysema in a Chinese population. Kaohsiung J Med Sci. 2017;33(3):124–9.CrossRefGoogle Scholar
  14. 14.
    Hostettler KE, Zhong J, Papakonstantinou E, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res. 2014;12(15):157.CrossRefGoogle Scholar
  15. 15.
    Yu Z, Wang D, Zhou Z, He S, Chen A, Wang J. Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice. Biol Pharm Bull. 2012;35(5):731–6.CrossRefGoogle Scholar
  16. 16.
    Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434–45.CrossRefGoogle Scholar
  17. 17.
    Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.CrossRefGoogle Scholar
  18. 18.
    Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med. 2016;193(2):178–85.CrossRefGoogle Scholar
  19. 19.
    Corte T, Bonella F, Crestani B, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015;24(16):116.CrossRefGoogle Scholar
  20. 20.
    Richeldi L, Kreuter M, Selman M, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2018;73(6):581–3.CrossRefGoogle Scholar
  21. 21.
    Crestani B, Quaresma M, Kaye M, Stansen W, Stowasser S, Kreuter M. Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON. Eur Respir J. 2017;50(Supp 61):OA3402.Google Scholar
  22. 22.
    Taniguchi H, Xu Z, Azuma A, et al. Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. Respirology. 2016;21(8):1425–30.CrossRefGoogle Scholar
  23. 23.
    Azuma A, Taniguchi H, Inoue Y, et al. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: a subgroup analysis of the INPULSIS® randomized trials. Respirol Carlton Vic. 2017;22(4):750–7.CrossRefGoogle Scholar
  24. 24.
    Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, IPFnet investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73.CrossRefGoogle Scholar
  25. 25.
    Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Pulm Pharmacol Ther. 2016;40:95–103.CrossRefGoogle Scholar
  26. 26.
    Jones PW, Quirk FH, Baveystock CM. The St George’s respiratory questionnaire. Respir Med. 1991;85(Suppl B):25–31.CrossRefGoogle Scholar
  27. 27.
    Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med. 2016;113:74–9.CrossRefGoogle Scholar
  28. 28.
    Huang H, Peng X, Zhong C. Idiopathic pulmonary fibrosis: the current status of its epidemiology, diagnosis, and treatment in China. Intractable Rare Dis Res. 2013;2(3):88–93.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Swigris JJ, Esser D, Conoscenti CS, Brown KK. The psychometric properties of the St George’s Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes. 2014;20(12):124.CrossRefGoogle Scholar
  30. 30.
    Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012;141(1):222–31.CrossRefGoogle Scholar
  31. 31.
    Rodríguez-Portal JA. Efficacy and safety of nintedanib for the treatment of idiopathic pulmonary fibrosis: an update. Drugs RD. 2018;18(1):19–25.CrossRefGoogle Scholar
  32. 32.
    Wang F-S, Fan J-G, Zhang Z, Gao B, Wang H-Y. The global burden of liver disease: the major impact of China. Hepatol Baltim Md. 2014;60(6):2099–108.CrossRefGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  • Zuojun Xu
    • 1
  • Huiping Li
    • 2
  • Fuqiang Wen
    • 3
  • Chunxue Bai
    • 4
  • Ping Chen
    • 5
  • Feng Fan
    • 6
  • Na Hu
    • 6
  • Susanne Stowasser
    • 7
  • Jian Kang
    • 8
    Email author
  1. 1.Department of Respiratory DiseasesPeking Union Medical College HospitalBeijingChina
  2. 2.Department of Respiratory DiseasesShanghai Pulmonary HospitalShanghaiChina
  3. 3.Department of Respiratory Diseases, West China HospitalSichuan UniversityChengduChina
  4. 4.Department of Respiratory Diseases, Zhongshan HospitalFudan UniversityShanghaiChina
  5. 5.Department of Respiratory DiseasesThe General Hospital of Shenyang Military RegionShenyangChina
  6. 6.Boehringer Ingelheim (China) Investment Co LtdShanghaiChina
  7. 7.Boehringer Ingelheim International GmbHIngelheim am RheinGermany
  8. 8.Department of Respiratory DiseasesThe First Hospital of China Medical UniversityShenyangChina

Personalised recommendations